Mechanism of Qiguiyin Decoction Treats Pulmonary Infection Caused by Pseudomonas aeruginosa Based on Gut Microbiota and Metabolomics
Xuran Cui,Xiaolong Xu,Yahui Hu,Rui Li,Qingquan Liu
DOI: https://doi.org/10.2147/IDR.S405033
2023-05-18
Infection and Drug Resistance
Abstract:Xuran Cui, 1– 3 Xiaolong Xu, 1– 3 Yahui Hu, 1, 3 Rui Li, 1, 3 Qingquan Liu 1– 3 1 Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, People's Republic of China; 2 Beijing Institute of Chinese Medicine, Beijing, 100010, People's Republic of China; 3 Beijing Key Laboratory of Basic Research with Traditional Chinese Medicine on Infectious Diseases, Beijing, 100010, People's Republic of China Correspondence: Qingquan Liu, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Gallery Backstreet No.23, Dongcheng District, Beijing, 100010, People's Republic of China, Tel +8613910055687, Email Background: Qiguiyin decoction (QGYD) was a traditional Chinese medicine (TCM) used to treat Pseudomonas aeruginosa infection in China. This study investigated the therapeutic effect and the potential mechanism of QGYD on carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection. Materials and Methods: Pulmonary infections were induced in mice by CRPA. The therapeutic effect of QGYD was evaluated by lung index and pulmonary pathology. The potential effects of QGYD on intestinal flora were detected by gut microbiome. The overall metabolism regulation of QGYD in blood was investigated by metabonomics. Next, the correlation between intestinal flora and metabolites was analyzed to illustrate the relationship between the regulatory effects of QGYD on metabolites and the beneficial effects of intestinal flora. Results: QGYD has significant therapeutic effect on CRPA infection. QGYD profoundly inhibited the excessive accumulation of Deferribacteres and Mucispirillum at phylum and genus levels, respectively. Eleven potential metabolites that were abnormally expressed by CRPA infection and significantly reversed by QGYD were identified. Ten of the eleven metabolites significantly regulated by QGYD were related to Deferribacteres. Deferribacteres showed significant positive correlation with DL-lactic acid, phenylalanine and other metabolites and significant negative correlation with vitamin k1. At the genus level, Mucispirillum was closely related to metabolites significantly regulated by QGYD. Mucispirillum was positively correlated with metabolites such as Dl-lactate and negatively correlated with vitamin k1. Conclusion: QGYD can improve CRPA infection and has the effect of regulating intestinal flora and metabolism. It was a promising drug against infection. Keywords: infection, drug-resistant bacteria, traditional Chinese medicine, Qiguiyin Decoction, pharmacodynamic mechanism Carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a growing threat to global public health as it causes high morbidity and mortality. It has been classified by the World Health Organization (WHO) as a critical pathogen requiring urgent research and development of effective new antibiotic therapies. 1,2 Especially for multi-drug resistant CRPA, only a few drugs can inhibit it. These limited options make the treatment of infected patients very challenging, and the development of new antibacterial drugs has become a major problem that the medical community must address. 3 Traditional Chinese medicine (TCM) is a valuable natural resource and a huge treasure trove in the drug discovery process. 4 Existing studies have proved that TCM can inhibit and kill bacteria. Meanwhile, they can also regulate the body's microecology and metabolism, and have definite curative effects and obvious advantages in the prevention and treatment of infectious diseases. 5,6 Qiguiyin decoction (QGYD) is a Chinese herbal compound developed according to many years of clinical experience in treating drug-resistant bacterial infection. 7 The prescription is composed of astragalus, angelica, Lonicera japonica Thunb., Reynoutria japonica Houtt., Artemisia annua L., etc., and has remarkable efficacy in the treatment of PA infection. Previous studies exhibited that QGYD have the function of delay and reverse PA resistance to antibiotics, modulate inflammation and immune disorders, and enhance clinical curative effect against PA infection. 8,9 However, the pharmacodynamic mechanism of QGYD on CRPA infection remains unclear. Studies have shown that the gut and lungs interact with each other when pulmonary infectious diseases occur. Respiratory pathogens, such as bacteria, lead to the disturbance of host symbiotic bacterial diversity, which may subsequently cause lung injury and affect intestinal function in host. Regulating intestinal flora to improve intestinal function helps to -Abstract Truncated-
pharmacology & pharmacy,infectious diseases